179 related articles for article (PubMed ID: 38338834)
21. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
22. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
23. Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer.
Gustafson B; Douglass L; Pluard T; Subramanian J
Mo Med; 2023; 120(4):314-317. PubMed ID: 37609465
[TBL] [Abstract][Full Text] [Related]
24. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
25.
Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
[No Abstract] [Full Text] [Related]
26. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
[TBL] [Abstract][Full Text] [Related]
27. Sotorasib: a KRAS
Ganguly A; Yoo E
Trends Pharmacol Sci; 2022 Jun; 43(6):536-537. PubMed ID: 35461718
[No Abstract] [Full Text] [Related]
28. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
29. Sotorasib for previously treated colorectal cancers with KRAS
Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
[TBL] [Abstract][Full Text] [Related]
30. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
31. Absorption, Distribution, Metabolism, and Excretion of [
Dahal UP; Rock BM; Rodgers J; Shen X; Wang Z; Wahlstrom JL
Drug Metab Dispos; 2022 May; 50(5):600-612. PubMed ID: 35153196
[TBL] [Abstract][Full Text] [Related]
32. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
33. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
[TBL] [Abstract][Full Text] [Related]
34. KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.
Gallina FT; Marinelli D; Melis E; Forcella D; Taje R; Buglioni S; Visca P; Torchia A; Cecere FL; Botticelli A; Santini D; Ciliberto G; Cappuzzo F; Facciolo F
Lung Cancer; 2023 Jul; 181():107254. PubMed ID: 37253296
[TBL] [Abstract][Full Text] [Related]
35. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
36. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
[TBL] [Abstract][Full Text] [Related]
37. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H
Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609
[TBL] [Abstract][Full Text] [Related]
38. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
39. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
40. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
Boby JM; Mohd Ghazali NN; Mani A; George M
J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
